Tag: osé
OSE Immunotherapeutics Presents New Data on Tedopi® in Phase 3 Clinical Trial in Patients With Advanced Non-Small Cell Lung Cancer After Failure of Immune Checkpoint Inhibitor Treatment, at ESMO Conference 2022 – 09/05/2022 at 07:30
Nantes, France – September 5, 2022, 7:30 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces the presentation of new analyzes on the phase 3 Atalante-1 trial of the…
OSE Immunotherapeutics announces the appointment of Alexis Vandier as Chief Executive Officer – 2022-07-13 18:00
Nantes, France – July 13, 2022, 6:00 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) is pleased to announce the appointment of Alexis Vandier as Chief Executive Officer, effective…
OSE Immunotherapeutics: Appoints New Chief Executive Officer
(CercleFinance.com) – OSE Immunotherapeutics announces this evening the appointment of Alexis Vandier as Chief Executive Officer, with immediate effect. He will thus succeed Alexis Peyroles who led the Company untilJanuary…
OSE Immunotherapeutics: appoints a new CEO – 07/13/2022 at 18:09
(CercleFinance.com) – OSE Immunotherapeutics announces this evening the appointment of Alexis Vandier as Chief Executive Officer, with immediate effect. He will thus succeed Alexis Peyroles who led the Company until…
Pharnext: recruits the legal director of OSE Immuno
(CercleFinance.com) – Pharnext announces today the appointment of Antoine Gravelle as Chief Legal Officer, effective July 1, 2022. A confirmed specialist in Law applied to the Health industries, Antoine Gravelle…
Ose Immuno: the title benefits from a broker analysis – 06/17/2022 at 16:47
(CercleFinance.com) – The Ose Immunotherapeutics share gained almost 6% in Paris, benefiting from a positive analysis by Invest Securities which maintained its buy opinion on the share and its price…
Ose Immuno: the title benefits from a broker analysis
(CercleFinance.com) – The Ose Immunotherapeutics share gained almost 6% in Paris, benefiting from a positive analysis by Invest Securities which maintained its buy opinion on the share and its price…
Ose immuno: Six experts join the scientific council
Read also (CercleFinance.com) – OSE Immunotherapeutics announces the appointment of six leading international experts to its new Scientific Board to support the Company in its new phase of growth and…
OSE Immuno: six experts join the scientific council
(CercleFinance.com) – OSE Immunotherapeutics announces the appointment of six leading international experts to its new Scientific Board to support the Company in its new phase of growth and its scientific…
OSE Immunotherapeutics will present four posters on Tedopi®, a combination of neo-epitopes in immuno-oncology, at the ASCO 2022 congress – 05/23/2022 at 18:00
Nantes, France – May 23, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) and its clinical partners GERCOR, ARCAGY-GINECO and the FoRT Foundation (Fondazione Ricerca Traslazionale) announce…
Presentations by OSE Immunotherapeutics at upcoming international congresses in London and Boston: ‘Immuno-Oncology Summit Europe’ and ‘Tumor Myeloid-Directed Therapies Summit’ – 05/11/2022 at 6:00 p.m.
Presentations on CLEC-1, a new myeloid checkpoint inhibitor target In cancer immunotherapy Nantes, France – May 11, 2022, 6 p.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) has been…
Ose Immuno and Boehringer Ingelheim Announce First Patient Treated in Phase 1 Expansion Clinical Trial of BI 765063
By Claude Leguilloux Published on 05/03/2022 at 6:20 p.m. Photo credit © Reuters …